Status
Conditions
Treatments
About
The overall objective of this study is to collect preliminary safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with burns and patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.
Full description
The primary objective is to assess hypoxic RBCs safety and tolerance assessment up to 24 hours following the transfusion initiation and overall up to 7 days (+/- 1 day) after the transfusion episode (single transfusion course).
Secondary objectives include the following.
Assessment of pre and post transfusion hemoglobin levels
Assessment of hemoglobin level before the following transfusion, if applicable
Assessment of AEs occurrence:
i. Up to 7 days (+/- 1 day) post transfusion, in comparison with historical control (including but not limited to infection, deep vein thrombosis, acute respiratory distress syndrome, transfusion-related acute lung injury, transfusion associated circulatory overload, anaphylactic shock, acute hemolytic transfusion reaction).
ii. Up to the subsequent transfusion episode or up to 28 days (+/- 1 day) after the initial transfusion, whichever comes first.
iii. From enrollment, up to their subsequent transfusion or 28 days (+/- 1 day) post transfusion, whichever comes first, through the assessment of patient's diary.
Assessment of the vital signs during and up to 15 minutes after the transfusion.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
A. Hematological malignancies patients group:
B. Burn patients group:
Exclusion criteria
A. Both patients groups
B. Burn patients specific exclusion criteria :
20 participants in 2 patient groups
Loading...
Central trial contact
Kimberly Dorsch
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal